Impact of Somatic DNA Repair Mutations on the Clinical Outcomes of Bone Metastases from Castration-Resistant Prostate Cancer.
DDR deficiency
DNA damage repair
SRE
bone metastases
liquid biopsy
mCRPC
prostate cancer
sheletal related events
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
04 Aug 2023
04 Aug 2023
Historique:
received:
07
07
2023
revised:
01
08
2023
accepted:
01
08
2023
medline:
14
8
2023
pubmed:
12
8
2023
entrez:
12
8
2023
Statut:
epublish
Résumé
Up to 80% of castration-resistant prostate cancer (CRPC) patients develop bone metastases during the natural history of disease and about 25% harbor mutations in DNA damage repair (DDR) genes. This retrospective observational study evaluated the prevalence of DDR alterations in CRPC patients and their effect on the clinical outcomes associated with bone metastases. The mutational status of CRPC patients was analyzed per FoundationOne
Identifiants
pubmed: 37569810
pii: ijms241512436
doi: 10.3390/ijms241512436
pmc: PMC10419855
pii:
doi:
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Semin Oncol. 2010 Oct;37 Suppl 2:S2-14
pubmed: 21111245
J Clin Oncol. 2019 Feb 20;37(6):490-503
pubmed: 30625039
Support Care Cancer. 2007 Jul;15(7):869-76
pubmed: 17262196
Nature. 2020 Feb;578(7793):82-93
pubmed: 32025007
Hum Mol Genet. 2002 Oct 1;11(21):2591-7
pubmed: 12354784
J Mol Cell Biol. 2014 Dec;6(6):442-57
pubmed: 25404613
Nat Genet. 2018 May;50(5):645-651
pubmed: 29610475
Lancet Oncol. 2020 Jan;21(1):162-174
pubmed: 31806540
J Clin Oncol. 2020 Nov 10;38(32):3763-3772
pubmed: 32795228
N Engl J Med. 2016 Aug 4;375(5):443-53
pubmed: 27433846
Nat Rev Urol. 2014 Jan;11(1):18-31
pubmed: 24296704
Cancer. 2007 Oct 15;110(8):1860-7
pubmed: 17763372
J Clin Oncol. 2013 May 10;31(14):1748-57
pubmed: 23569316
N Engl J Med. 2020 Dec 10;383(24):2345-2357
pubmed: 32955174
Cancer Treat Rev. 2017 Jun;57:16-27
pubmed: 28527407
J Clin Oncol. 2018 Apr 10;36(11):1080-1087
pubmed: 29384722
Radiother Oncol. 2005 Mar;74(3):259-65
pubmed: 15763306
Clin Cancer Res. 2022 Apr 14;28(8):1518-1530
pubmed: 35091440
Cancer Discov. 2018 Apr;8(4):444-457
pubmed: 29367197
Cell. 2018 Jun 14;173(7):1770-1782.e14
pubmed: 29906450
Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1276-83
pubmed: 25808631
JAMA Oncol. 2018 Jun 1;4(6):868-870
pubmed: 29242909
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Lancet Oncol. 2019 May;20(5):686-700
pubmed: 30987939
Crit Rev Oncol Hematol. 2020 Feb;146:102864
pubmed: 31986318
Nature. 2019 Jul;571(7766):576-579
pubmed: 31292550
World J Mens Health. 2022 Jul;40(3):368-379
pubmed: 34448375
Mol Cancer Res. 2009 Jul;7(7):1110-8
pubmed: 19584259
Endocr Relat Cancer. 2014 May 08;21(3):487-93
pubmed: 24741024
Br J Cancer. 2021 Oct;125(9):1226-1232
pubmed: 34333554
Dis Markers. 2016;2016:4358292
pubmed: 27594734
Cancer Treat Rev. 2001 Jun;27(3):165-76
pubmed: 11417967
Ann Oncol. 2005 Apr;16(4):579-84
pubmed: 15734776
J Natl Cancer Inst. 2018 Sep 1;110(9):1030-1034
pubmed: 29506079
Eur Urol. 2019 Mar;75(3):368-373
pubmed: 30773204
JCO Precis Oncol. 2017 Jul;2017:
pubmed: 28825054
Oncotarget. 2016 Jun 21;7(25):37839-37845
pubmed: 27191887
Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2035-2044
pubmed: 29922948
JAMA Netw Open. 2020 Oct 1;3(10):e2021692
pubmed: 33112397
Support Care Cancer. 2008 Aug;16(8):879-89
pubmed: 18392862
J Urol. 2006 Feb;175(2):552-6
pubmed: 16406994
Clin Genitourin Cancer. 2015 Feb;13(1):39-43
pubmed: 24999168
N Engl J Med. 2015 Oct 29;373(18):1697-708
pubmed: 26510020
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571